[ad_1]
New Offering Enhances Portfolio of Leading COVID-19 PCR Testing Options
Combined Kit Provides People with Trusted Answers from the Comfort of Their Homes
Labcorp (NYSE:LH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006327/en/
Photo courtesy of Labcorp
The Pixel by Labcorp COVID-19+Flu+RSV Test Home Collection Kit will be available for use by individuals age 2 and older through the Labcorp OnDemand™ digital health platform without a prescription. For those who meet clinical guidelines and have insurance, the kit is available at no upfront cost. By using the Labcorp kit to determine whether they have contracted COVID-19, flu or RSV, individuals are choosing the reliability of PCR testing—considered the gold standard for diagnosing COVID-19 and its variants—to make key health decisions.
“Labcorp’s COVID-19 tests …
Full story available on Benzinga.com
[ad_2]
Source link
